A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

NCT03125746 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: LXI-15029
DRUG: LXI-15029+Exemestane

Sponsor

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.